Allogene’s CAR T clinical trial advances with CIRM grant

Allogene Therapeutics has received a grant of $15m from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of its allogeneic CAR T product, ALLO-316.

ALLO-316 is an AlloCAR T investigational product that targets CD70 being developed to treat advanced or metastatic renal cell carcinoma (RCC).